1. Home
  2. GE vs GILD Comparison

GE vs GILD Comparison

Compare GE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo General Electric Company

GE

General Electric Company

HOLD

Current Price

$311.34

Market Cap

318.8B

Sector

Technology

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$138.88

Market Cap

173.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GE
GILD
Founded
1892
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.8B
173.9B
IPO Year
2008
2001

Fundamental Metrics

Financial Performance
Metric
GE
GILD
Price
$311.34
$138.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
18
Target Price
$331.17
$147.89
AVG Volume (30 Days)
5.2M
4.9M
Earning Date
04-21-2026
04-24-2026
Dividend Yield
0.61%
2.36%
EPS Growth
35.89
1684.21
EPS
8.14
6.78
Revenue
$45,855,000,000.00
$24,689,000,000.00
Revenue This Year
$8.35
$4.65
Revenue Next Year
$10.31
$5.96
P/E Ratio
$37.85
$20.48
Revenue Growth
18.48
9.98
52 Week Low
$176.02
$95.30
52 Week High
$348.48
$157.29

Technical Indicators

Market Signals
Indicator
GE
GILD
Relative Strength Index (RSI) 55.47 45.19
Support Level $307.87 $133.89
Resistance Level $312.50 $141.70
Average True Range (ATR) 8.41 3.09
MACD 4.02 0.27
Stochastic Oscillator 92.05 54.63

Price Performance

Historical Comparison
GE
GILD

About GE General Electric Company

GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft turbine engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 80,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: